BioNTech SE vs Moderna, Inc.: Strategic Comparison

This in-depth comparison examines BioNTech SE and Moderna, Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching BioNTech SE on its own, evaluating Moderna, Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between BioNTech SE and Moderna, Inc. is widest.

On the headline numbers, BioNTech SE reports annual revenue of ~$3.2B against $1.9B for Moderna, Inc., while their respective market capitalizations stand at $24.7B and $72.7B. BioNTech SE is headquartered in Germany and Moderna, Inc. operates from United States, and those different home markets shape how each company competes.

BioNTech SE: BioNTech SE is a German biotechnology company headquartered in Mainz and listed on Nasdaq as BNTX. Physicians Ugur Sahin and Özlem Türeci founded it in 2008 with oncologist Christoph Huber to build individualized cancer immunotherapies on mRNA. That platform became Comirnaty, the Pfizer-BioNTech COVID-19 vaccine first authorized in December 2020, which earned BioNTech ~$11.6 billion (€10.29 billion) of net profit in 2021. Since 2023 the company has redirected the windfall into oncology: it bought Biotheus for full rights to pumitamig, licensed antibody-drug conjugates, partnered pumitamig with Bristol Myers Squibb, and acquired mRNA rival CureVac in December 2025. It had 7,807 employees at the end of 2025.

Moderna, Inc.: Moderna, Inc. is a Nasdaq-listed biotechnology company headquartered in Cambridge, Massachusetts. It develops medicines that deliver mRNA instructions into cells so the body produces a target protein, such as a viral antigen or tumor neoantigen. As of 2026 it markets COVID-19 vaccines (Spikevax, mNEXSPIKE), an RSV vaccine (mRESVIA) and a flu vaccine (mFLUSIVA), and co-develops the individualized cancer therapy intismeran autogene with Merck.

BioNTech SE and Moderna, Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between BioNTech SE and Moderna, Inc..

BioNTech SE business model: BioNTech earns most of its revenue from Comirnaty. In most markets Pfizer sells the vaccine and the two companies split gross profit 50:50, so BioNTech books only its share; in Germany BioNTech records direct sales as revenue, and Fosun Pharma holds rights in Greater China. The second revenue line is partnerships: Bristol Myers Squibb paid $1.5 billion upfront in 2025 for a 50:50 share of pumitamig and owes $2 billion in non-contingent anniversary payments through 2028, and BioNTech expects to recognize ~$693 million (€613 million) of BMS collaboration revenue in Q3 2026. Smaller amounts come from a pandemic-preparedness contract with the German government and service businesses. The long-term plan is to sell its own cancer medicines, which is why sales and marketing spending is rising ahead of planned launches.

Moderna, Inc. business model: Moderna earns most of its revenue from net product sales of mRNA vaccines: Spikevax and mNEXSPIKE for COVID-19, mRESVIA for RSV, and from the 2026-2027 season mFLUSIVA for influenza. Buyers are governments, national immunization programs, pharmacy chains, wholesalers and health systems, so sales are concentrated in the autumn and winter vaccination season. Smaller amounts come from collaboration, licensing and grant revenue. Because every product uses the same mRNA and lipid nanoparticle backbone, Moderna can reuse manufacturing, regulatory and clinical know-how across programs, while partners such as Merck share development costs and profits on the individualized cancer vaccine intismeran autogene.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of BioNTech SE stack up against those of Moderna, Inc..

BioNTech SE competitive advantage: BioNTech's edge is breadth backed by a large balance sheet. It pairs mRNA know-how proven across billions of vaccine doses with a PD-L1xVEGF-A bispecific (pumitamig) co-developed with Bristol Myers Squibb, HER2 and B7-H3 antibody-drug conjugates from Duality Biologics, the CTLA-4 candidate gotistobart from OncoC4, and individualized mRNA cancer vaccines developed with Genentech. With ~$18.8 billion (€16.6 billion) in cash and securities at mid-2026 and BMS sharing pumitamig costs, it can run more late-stage trials at once than most biotechs: 14 pivotal trials were ongoing in August 2026. Buying CureVac in December 2025 also brought a rival mRNA patent estate in-house.

Moderna, Inc. competitive advantage: Moderna's advantages are a validated mRNA and lipid nanoparticle platform, a large patent estate on modified mRNA, in-house manufacturing in Norwood, Massachusetts plus onshore plants in the UK, Canada and Australia, and regulatory experience across five FDA-approved products. The same platform produced the first FDA-approved mRNA flu vaccine (2026) and the first individualized neoantigen therapy to succeed in a Phase 3 trial.

Future prospects matter as much as current results. The growth strategies below explain how BioNTech SE and Moderna, Inc. each plan to expand from here.

BioNTech SE growth strategy: BioNTech's stated goal is to become a multi-product oncology company by 2030. The plan rests on three groups of medicines: next-generation immunomodulators led by pumitamig, now in seven pivotal trials across lung, breast, colorectal and gastric cancer, and gotistobart; antibody-drug conjugates such as trastuzumab pamirtecan (HER2) and elfetabart drozuntecan (B7-H3), which has been given to more than 1,000 patients; and mRNA cancer immunotherapies including autogene cevumeran with Genentech. It is testing these assets together in more than ten novel-novel combinations, cutting non-focus programs, and handing all COVID-19 vaccine manufacturing to Pfizer to free cash for the clinic. Next-generation mRNA platform work is to be contributed to the founders' new company.

Moderna, Inc. growth strategy: Moderna is narrowing its pipeline to programs with near-term commercial potential: respiratory vaccines (COVID, RSV, flu and combinations), individualized cancer therapy with Merck, and a small set of rare-disease and latent-virus programs. It cut R&D spending, reduced headcount below 5,000 in 2025, and is seeking expanded age and country approvals for existing vaccines while preparing filings for intismeran autogene.

A closer look at the financial trajectory of BioNTech SE and Moderna, Inc. rounds out the comparison.

BioNTech SE: BioNTech went from a ~$202 million (€179.1 million) net loss in 2019 to ~$11.6 billion (€10.29 billion) of net profit on ~$21.4 billion (€18.98 billion) of revenue in 2021, almost all from Comirnaty. Revenue then fell to ~$19.6 billion (€17.31 billion) in 2022, ~$4.32 billion (€3.82 billion) in 2023 and ~$3.11 billion (€2.75 billion) in 2024, when it posted a ~$752 million (€665.3 million) net loss. FY2025 revenue rose 4.3% to ~$3.24 billion (€2.87 billion) only because BMS collaboration revenue was booked in Q3, while the net loss widened to ~$1.29 billion (€1.14 billion) on ~$2.37 billion (€2.10 billion) of R&D and legal settlement costs. In 2026 the decline resumed: H1 revenue fell to ~$253 million (€223.7 million), the H1 net loss reached ~$1.53 billion (€1.35 billion), and full-year revenue guidance was cut to €1.6-1.9 billion. The cushion is ~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026, which also funds a $1.0 billion ADS buyback launched in May 2026.

Moderna, Inc.: Moderna went from $803 million of revenue in 2020 to $18.5 billion in 2021 and $19.3 billion in 2022, earning $12.2 billion and $8.4 billion of net income in those years. Revenue then fell to $6.8 billion in 2023, $3.2 billion in 2024 and $1.94 billion in 2025, with net losses of $4.7 billion, $3.6 billion and $2.8 billion. In 2025 Moderna cut operating expenses by about $2.2 billion (roughly 30%) and ended the year with $8.1 billion in cash and investments. Q2 2026 revenue was $145 million with a $782 million net loss; management guided to up to 10% revenue growth for 2026 and cash costs of about $4 billion.